Citigroup Issues Pessimistic Forecast for Bio-Techne (NASDAQ:TECH) Stock Price

Key Points

• Citigroup cut its price target on Bio‑Techne from $80 to $70 but maintained a "buy" rating, implying roughly 37.5% upside from the prior close.
• Q3 results missed estimates — EPS $0.53 vs. $0.55 and revenue $311.4M vs. $316.1M — and analysts cite demand headwinds, while management expects Q4 organic growth to be about flat, targets ~100 basis points of margin expansion, and declared a $0.08 quarterly dividend.
• Several firms trimmed targets (Wells Fargo to $62) leaving a consensus "Moderate Buy" with an average target of $66.77, yet the stock still traded up 7.4% to $50.91 on heavy volume and has ~99% institutional ownership.

Bio-Techne (NASDAQ:TECH - Get Free Report) had its price target dropped by stock analysts at Citigroup from $80.00 to $70.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Citigroup's price target suggests a potential upside of 37.50% from the stock's previous close.

A number of other research firms also recently commented on TECH. Wells Fargo & Company decreased their price target on Bio-Techne from $76.00 to $62.00 and set an "overweight" rating for the company in a report on Thursday. Benchmark reissued a "buy" rating on shares of Bio-Techne in a report on Tuesday, February 3rd. Robert W. Baird set a $49.00 price target on Bio-Techne in a report on Thursday. Stifel Nicolaus set a $50.00 price target on Bio-Techne in a report on Thursday. Finally, Weiss Ratings downgraded Bio-Techne from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $66.77.

Bio-Techne Trading Up 7.4%

TECH stock traded up $3.51 during trading on Thursday, hitting $50.91. The company had a trading volume of 5,145,535 shares, compared to its average volume of 2,468,156. The firm has a market capitalization of $7.96 billion, a P/E ratio of 99.83, a PEG ratio of 3.73 and a beta of 1.41. Bio-Techne has a 52-week low of $45.12 and a 52-week high of $72.16. The company has a 50 day simple moving average of $54.55 and a 200-day simple moving average of $59.61. The company has a quick ratio of 3.08, a current ratio of 4.54 and a debt-to-equity ratio of 0.13.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.02). Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The firm had revenue of $311.42 million for the quarter, compared to analysts' expectations of $316.11 million. During the same quarter in the prior year, the business posted $0.56 EPS. The business's quarterly revenue was down 1.5% on a year-over-year basis. As a group, research analysts forecast that Bio-Techne will post 1.73 earnings per share for the current fiscal year.

Institutional Trading of Bio-Techne

Institutional investors and hedge funds have recently made changes to their positions in the business. Danske Bank A S acquired a new position in Bio-Techne during the fourth quarter worth $29,000. eCIO Inc. acquired a new position in Bio-Techne during the fourth quarter worth $30,000. Measured Wealth Private Client Group LLC acquired a new position in Bio-Techne during the third quarter worth $32,000. iSAM Funds UK Ltd acquired a new position in Bio-Techne during the third quarter worth $33,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Bio-Techne by 506.3% during the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company's stock worth $35,000 after buying an additional 562 shares during the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

More Bio-Techne News

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Management said it expects Q4 organic growth to be approximately flat while targeting ~100 basis points of operating-margin expansion, which investors often view as a path to better profitability even with near-term top-line pressure. Article Title
• Positive Sentiment: Bio-Techne’s board declared a $0.08 quarterly dividend (payable May 29, ex-date May 18), which supports income-focused investors and signals confidence in cash flow. Article Title
• Positive Sentiment: Wells Fargo lowered its price target from $76 to $62 but maintained an "Overweight" rating — a vote of confidence in the company’s prospects that may limit further downside. Article Title
• Neutral Sentiment: Full earnings call transcript and company release provide detail on segment performance (strength in Proteomic Analysis, Spatial Biology, GMP proteins) and management commentary for investors doing deeper diligence. Article Title Press Release
• Negative Sentiment: Q3 results missed consensus: revenue of ~$311.4M was below estimates and down ~2% year-over-year, and adjusted EPS of $0.53 missed the ~$0.55 consensus — top-line softness triggered selling pressure. Article Title
• Negative Sentiment: Analysts and press flagged demand headwinds from U.S. academic funding cuts and timing of large commercial shipments (including prior-year GMP fast‑track orders), which pressures near-term organic growth. Article Title

Bio-Techne Company Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.